Momentous Data For Oxford/Novavax Malaria Vaccine
First To Achieve WHO's 75% Efficacy Goal
Executive Summary
A year to the day since the first dose of its COVID-19 vaccine was given, Oxford University's Jenner Institute has unveiled stellar findings from a Phase IIb trial of its malaria vaccine.
You may also be interested in...
GSK’s Malaria Vaccine To Be Made By Bharat Biotech For WHO
GSK is transferring technology for the manufacture of its malaria vaccine antigen to Bharat Biotech and by 2029 will also transfer rights to supply the vaccine to WHO-approved immunization programs. The deal is expected to improve access via lower costs for such programs.
Building A Bridge For Europe's Budding Microbiome Biotechs
Two biotech start-up studios have been launched to nurture new ventures in the microbiome and synthetic biology fields, with cash already gone into three of them: Omne Possibile, Stellate Therapeutics and NovoBiome.
More Competition Coming To Cushing's Market
Having been given a PDUFA target date of 1 January, 2022, Strongbridge is already preparing for a happy new year challenging Recordati's Isturisa for market share in the Cushing's syndrome space